Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...
Eli Lilly and Indiana University signed a $40 million research agreement on Dec. 3 that will beef up the availability and accessibility of clinical trials in Indiana. Under the agreement, Lilly will ...
Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...
Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...
Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...
The booming market for weight-loss drugs has propelled Eli Lilly LLY1.16%increase; green up pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...
Nov. 21 (UPI) --Healthcare giant Eli Lilly on Friday became the first global healthcare company to hit $1 trillion in value. The Indiana-based company hit the $1 trillion market capitalization ...
Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results